Related Experiment Video
Updated: May 16, 2026

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Abiraterone and its place in the treatment of metastatic CRPC
1Department of Medicine, Tulane Medical School, Box SL-42, 1430 Tulane Avenue, New Orleans, LA 70112, USA. osartor@tulane.edu
Nature Reviews. Clinical Oncology
|November 15, 2012
Abstract:
An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.

